Meeting
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
Authors
John Leonard Fox
Illumina, San Diego, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3124)
DOI
10.1200/JCO.2023.41.16_suppl.3124
Abstract #
3124
Poster Bd #
322
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Quality Care Symposium
Biomarker testing patterns and use of targeted therapy in Medicare Fee-for-Service (FFS) beneficiaries newly diagnosed with metastatic non-small cell lung cancer (mNSCLC).
First Author: Anik Patel
Poster
2021 ASCO Annual Meeting
Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).
First Author: Shingo Matsumoto
Poster
2020 ASCO Virtual Scientific Program
MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA.
First Author: Emily S. Lebow
Poster
2018 ASCO Annual Meeting
Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.
First Author: Nathan A. Pennell